Role of Autologous Fibrin Glue (AFG) to Reduce Drainage Volume After Modified Radical Mastectomy for Breast Cancer

Yohana Azhar, Ahmad Iffa Maududy, Nadjwa Zamalek Dalimoenthe

Abstract


Background: Seroma is arguably the most significant complication that can happen after mastectomy. Although seroma is not a life-threatening complication, this condition can lead to severe morbidities. This situation can cause prolonged hospital stays and delayed adjuvant therapy. In this regard, autologous fibrin glue is a hemostatic agent that can accelerate fibrin formation, stop vascular oozing, and decrease dead space. Therefore, this research was performed to evaluate autologous fibrin glue function in lowering seroma volume after mastectomy and shortening the length of hospital stay.

Methods: This randomized control trial research was designed to compare the effect of autologous fibrin glue to a control group that did not receive autologous fibrin glue. Seroma volume was calculated every 24 hours. The drains were then removed after the production of seroma less than 30 mL/24 hours.

Results: We recruited 20 patients for each of the two groups who met the inclusion criteria. Age, histopathology type, breast cancer stage, number of lymph nodes, and tumor size did not significantly differ. However, patients in the fibrin glue group had significantly lower cumulative drain production. The median seroma volume in the treatment group was 9.30 mL, while the median in the control group was 20.90 mL (p < 0.05).

Conclusions: Autologous fibrin glue significantly decreased seroma formation and length of hospital stay.


Keywords


autologous fibrin glue, breast cancer, mastectomy, seroma

References


Bray F, Ferlay J, Soerjomataram I, et al. Global cancer

statistics 2018: GLOBOCAN estimates of incidence

and mortality worldwide for 36 cancers in 185

countries. CA Cancer J Clin. 2018;68(6):394–424.

Azhar Y, Agustina H, Abdurahman M, Achmad D.

Breast cancer in West Java: Where do we stand

and go?. Indones J Cancer. 2020;14(3):91–6.

Akinci M, Cetin B, Aslan S, Kulacoglu H. Factors

affecting seroma formation after mastectomy with full

axillary dissection. Acta Chir Belg. 2009;109:481–483.

Junior NO. Hubungan antara seroma dengan body

mass index dan kadar lekosit cairan seroma. Surgical

Oncology Consultant [dissertation]. Bandung: Padjajaran University; 2010.

Pogson CJ, Adwani A, Ebbs SR. Seroma following breast cancer surgery. Eur J Surg Oncol. 2003;29:711–7.

Udén P, Aspegren K, Balldin G, et al. Fibrin adhesive

in radical mastectomy. Eur J Surg. 1993;159(5):263–5.

Langer S, Guenther JM, DiFronzo LA. Does fibrin

sealant reduce drain output and allow earlier removal

of drainage catheters in women undergoing operation

for breast cancer? Am Surg. 2003;69(1):77–81.

Carless PA, Henry DA. Systematic review and metaanalysis of the use of fibrin sealant to prevent

seroma formation after breast cancer surgery. Br J

Surg. 2006;93(7):810–9.

Düregger K, Frenzel S, Eblenkamp M. Autologous

fibrin glue: automated production and adhesive

quality. Curr Dir Biomed Eng. 2017;3:397–400.

Chang YT, Shih SL, Loh EW, Tam KW. Effects of

fibrin sealant on seroma reduction for patients with

breast cancer undergoing axillary dissection: metaanalysis of randomized controlled trials. Ann Surg

Oncol. 2020;27(13):5286–95.

R. Tasinato, M. Godina, L. Griggio et al., “Prevenzione

della linforrea ascellare nelle pazienti sottoposte a

linfadenectomia per carcinoma mammario,” Acta

Chirurgica Italica,1993;49, pp. 479–484

Cavichiolo, Benthien J, Buschle M, & Carvalho B.

Comparison of fibrin adhesives prepared by 3

different methods. International Archives of

Otorhinolaryngology, 2013; 17(1), 62–65. https://

doi.org/10.7162/S1809-97772013000100011


Full Text: PDF

DOI: 10.33371/ijoc.v15i4.826

Article Metrics

Abstract view : 141 times
PDF - 165 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.